Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
66 Leser
Artikel bewerten:
(0)

BIO-Europe Spring 2016 Event in Sweden this April will bring 2,000+ life science executives to Stockholm-Uppsala region

ZUG, Switzerland and STOCKHOLM, Feb. 2, 2016 /PRNewswire/ -- The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4-6, 2016. Organized by EBD Group, the event is co-hosted by Stockholm Business Region and Stockholm Science City Foundation.

The Stockholm-Uppsala region, defined as the three counties of Uppsala, Stockholm and Sörmland, is one of the largest life science clusters in Europe, and Scandinavia's leading life science cluster. It is also one of the world's most productive with an astounding 15-20 new life science companies formed on average in the region each year over the last decade.

"The Stockholm-Uppsala region offers life science companies access to cutting-edge research, unique competence and an infrastructure that brings innovations to patients," said Ylva Williams, CEO of Stockholm Science City Foundation."Our strength is in collaboration, where the industry have access to healthcare and patients through test beds. Sweden is an excellent choice for production of biologics, pilots within healthcare as well as for clinical trials. "

"Stockholm is an active life science cluster with over 600 companies based in the region, including industry leaders such as AstraZeneca and GE Healthcare," said Anna Chrisman, Group Managing Director, EBD Group. "As an innovation center for stem cell therapies, digital health and drug development R&D, it is the perfect place to hold BIO-Europe Spring."

BIO-Europe Spring is premier springtime partnering conference serving the global biotechnology industry and is facilitated by EBD Group's partneringONE®, the gold standard one-to-one networking solution for the life sciences.

One-to-one partnering meetings are a key business strategy that has transformed the drug development industry in bringing together innovators and visionaries with seasoned experts from every corner of the globe. Company presentations by early stage projects, innovative startups, established biotechs and midsize pharma companies are also a focus of the event and enable innovators to present directly to potential investors, pharma and development partners.

International large and midsize pharma companies already confirmed to attend include AbbVie, Alexion Pharmaceuticals, Almirall, Amgen, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Company, Fine Foods & Pharmaceuticals, Ironwood Pharmaceuticals, Johnson & Johnson, LES LABORATOIRES SERVIER, Merck Serono, a division of Merck KGaA, Darmstadt, MSD, Novartis Pharma, Novo Nordisk, Pfizer, Pierre Fabre Medicament, Roche, Sanofi, Takeda Pharmaceutical Company Ltd, and Upsher Smith.

The 2015 edition featured 12,439 one-to-one partnering meetings. Over 2,300 delegates from 1,367 companies representing 53 countries attended. There were 129 company presentations with 2,672 licensing opportunities on offer, and 68 exhibitors at the event.

Registration information for BIO-Europe Spring is available online.

Additional links and information:

Follow BIO-Europe Spring 2016 on Twitter: @EBDGroup (hashtag: BES16).

Online Press Kit service for BIO-Europe Spring 2016 is available from Virtual Press Office/PR Newswire to enhance your public relations efforts.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe's largest life science partnering conferences, supported by the Biotechnology Innovation Organization (BIO)
  • BioPharm America', the fastest growing partnering event in North America
  • Biotech Showcase', a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® Group
  • Biolatam®, facilitating partnering among global life sciences executives in Latin America's vibrant life science hubs

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.